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The protective effects of estrogen in the cardiovascular system result
from both systemic effects and direct actions of the hormone on the
vasculature. Two estrogen receptors have been identified, ERa and
ERb. We demonstrated previously that estrogen inhibits the response
to vascular injury in both wild-type and ERa-deficient mice, and that
ERb is expressed in the blood vessels of each, suggesting a role for
ERb in the vascular protective effects of estrogen. In the present
study, we examined the effect of estrogen administration on mouse
carotid arterial injury in ERb-deficient mice. Surprisingly, in ovariec-
tomized female wild-type and ERb knockout mice, 17b-estradiol
markedly and equally inhibited the increase in vascular medial area
and the proliferation of vascular smooth muscle cells after vascular
injury. These data demonstrate that ERb is not required for estrogen-
mediated inhibition of the response to vascular injury, and suggest
that either of the two known estrogen receptors is sufficient to
protect against vascular injury, or that another unidentified estrogen
receptor mediates the vascular protective effects of estrogen.
17b-estradiol u vascular smooth muscle
The cardiovascular protective effects of estrogen are well estab-lished, and the direct effects of the hormone on vascular tissues
are now well recognized (1, 2). Using a model of carotid arterial
injury in a mouse, we have shown previously that administration of
physiologic levels of 17b-estradiol (E2) completely inhibits the
vascular injury response in ovariectomized female wild-type (w.t.)
mice (3, 4). Subsequent studies demonstrated that E2 continues to
protect against vascular injury in ERa knockout mice (aERKO)
(4), indicating that estrogen can inhibit the vascular injury response
by an ERa-independent pathway. Another estrogen receptor,
termed ERb, was identified recently (5), suggesting the possibility
that ERb mediates the protective effects of E2 on the vasculature.
Studies demonstrating that ERb is expressed in vascular cells and
tissues (4, 6–11), and, in contrast to ERa, that ERb mRNA
expression increases in vascular endothelial and smooth muscle
cells after vascular injury (11, 12), prompted widespread specula-
tion that ERb may place a central role in mediating the cardiovas-
cular effects of E2 (10, 13, 14). To test directly the hypothesis that
ERb mediates the vasoprotective effects of estrogen, we have now
developed knockout mice in which the ERb gene is disrupted by
gene targeting (bERKO) (15). In the present study, we examine the
effect of estrogen on the response to vascular injury in these
bERKO mice.
Methods
Animals. The bERKO mice were generated by targeted disruption
of exon three of the ERb gene as described (15). The bERKO mice
are normal in appearance, but the females are subfertile because of
impaired ovarian function (15). For vascular injury studies, 3- to
4-month-old F2 littermates bred from heterozygote matings of F1
animals (129 3 C57BLy6J) were used. The mice were fed a normal
diet ad libitum, as previously described (3, 4).
Carotid Artery Injury. Ovariectomized F2 female mice (30 w.t. and 27
bERKO) underwent unilateral carotid artery injury under the
protocol described in detail previously (3, 4) (Fig. 1). Briefly, w.t.
and bERKO mice were ovariectomized, allowed to recover, and
then randomized to receive either placebo pellets (2E2) or E2-
containing pellets (1E2) (Innovation Research, Sarasota, FL) to
reestablish circulating physiological levels of E2 (3, 4). One week
after pellet implantation, endothelial denudation vascular injury
was produced by intraluminal introduction of a thin wire into the
left common carotid artery. Two weeks after injury, the animals
were anesthetized and killed and the uninjured and injured vessels
were harvested.
Morphometry and Immunohistochemistry. The response to vascular
injury was evaluated by measuring the medial area and by immu-
nohistologic assessment of vascular smooth muscle cell (VSMC)
proliferation (BrdU incorporation). Parallel sections from all 114
carotid arteries were stained for hematoxylinyeosin and for elastin,
and area measurements were made by using a computerized
morphometric analysis system on the elastin-stained sections (3, 4).
For each animal, two sections were analyzed, and the medial area
measurements were averaged. BrdU-labeled cells were identified
by immunostaining, and counted, as described (3, 4). All measure-
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Fig. 1. Design of the carotid artery injury study. All animals were ovariecto-
mized, and then allowed to recover for 7–10 days. Estrogen-containing (E2) or
vehicle-containing (V) pellets were implanted s.c. one week before the animals
underwent unilateral carotid injury and implantation of an osmotic minipump
containing BrdU. On day 14 after injury, the animals were anesthetized and
killed; both carotid arteries were perfusion-fixed, harvested, and embedded in
paraffin. Vessels were then sectioned transversely and stained to allow morpho-
metric and immunohistochemical analysis of the response to injury. Further
details of the procedure have been published previously (3, 4).











ments were made by two independent observers fully blinded to
treatment. To distinguish between different vascular cell types,
immunostaining was also performed on parallel carotid artery
sections with endothelial cell-specific factor VIII-related antigen
(Sigma) and VSMC-specific a-actin antibodies (Sigma) (3, 4).
Reverse Transcriptase-PCR. Random hexamer-primed reverse tran-
scription (RT) reactions were carried out with 1.25 mg of total RNA
(TriReagent, Sigma), derived from the aortae of w.t. or bERKO
mice, or from w.t. uterus. The primers for PCR included: (i)
ERb-specific forward primers, 59-25 (base pairs 25–46) and 59-38
(base pairs 38–59); (ii) ERb-specific reverse primers, 39-299 (base
pairs 299–278) and 39-798 (base pairs 798–787); (iii) ERa-specific
forward primers, 59-506 (base pairs 506–526) and 59-536 (base pairs
536–556); and (iv) ERa-specific reverse primers, 39-1185 (base
pairs 1185–1155) and 39-1147 (base pairs 1147–1127). These prim-
ers are based on the published coding sequences for murine ERa
(16) and ERb (5). The specificity of the primers was confirmed by
PCR with plasmids containing ERa and ERb cDNAs. Negative
controls, in which the RT enzyme was omitted, were included in all
experiments. The following PCR protocol was employed: 94°C for
5 min, followed by 32 cycles of 94°C for 1 min, 50°C for 1 min, 72°C
for 1 min, and a final 5-min extension at 72°C. In all cases, nested
PCR was then carried out on the initial PCR product by using
receptor-specific internal primers.
Statistical Analyses. For all analyses, within-group differences were
assessed with one-factor ANOVA; post hoc comparisons were
tested with the Student–Newman–Keuls test. P , 0.05 was consid-
ered significant.
Results
The expression of ERa and ERb mRNA in the vasculature of the
w.t. and bERKO mice was investigated by using reverse tran-
scriptase-PCR. ERb mRNA was expressed in low abundance in
Fig. 2. Reverse Transcriptase-PCR analysis of ERa and ERb expression in w.t. and
bERKOaortae.PCRwasperformedbyusingeitherERa-orERb-specificprimerson
the product of an RT reaction with RNA derived from w.t. (W) or bERKO (K)
aortae, or w.t. mouse uterus (U). The RT reaction was carried out in the absence
(2)orpresence (1)of reverse transcriptase.Primerpairswereselectedtoproduce
PCR products of 240 bp (ERb) or 611 bp (ERa). The PCR products were then
separated by agarose gel electrophoresis. A 100-bp DNA ladder (leftmost lane) is
provided as a comparison for evaluating the size of the PCR products.
Fig. 3. Medial areas of uninjured and injured (Uninj and Inj, respectively) w.t. and bERKO
mouse carotid arteries treated with vehicle or E2. (A–F) Representative segments from elastin-
stained carotid artery sections are shown (3400). The medial area of each section is listed
below. All area measurements were made on complete sections. (A) Wild-type uninjured
(Uninj, 16 3 1023 mm2). (B) Wild-type injured, vehicle-treated (Inj, 2E2; 23 3 1023 mm2). (C)
Wild type injured, E2-treated (Inj, 1E2; 17 3 1023 mm2). (D) bERKO (Uninj; 16 3 1023 mm2). (E)
bERKO (Inj, 2E2; 22 3 1023 mm2). (F) bERKO (Inj, 1E2; 15 3 1023 mm2). (G) Summary of medial
area data for all w.t. and bERKO mice (n 5 30 and n 5 27, respectively, for uninjured vessels,
and n 5 13–15 for each group of injured vessels). The medial areas did not differ between the
w.t. and bERKO mice, either in the injured, vehicle-treated groups (Inj 2E2; 20 6 0.9 3 1023
mm2 vs. 19.8 6 0.6 3 1023 mm2, respectively), or in the injured, E2-treated groups (Inj, 1E2;
17.8 6 0.6 1023 mm2 vs. 16.8 6 0.6 1023 mm2, respectively). In G, all data are shown as mean 6
SEM. *, P , 0.05, compared with both uninjured and injured estrogen-treated groups within
the same genotype.
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the vasculature of the w.t. mice (Fig. 2), confirming our previous
findings (4, 11, 12). As expected, ERb mRNA was not detectable
in the bERKO vessels. Furthermore, disruption of the ERb gene
in the bERKO mice had no effect on the level of vascular
expression of ERa mRNA (Fig. 2).
The response to vascular injury in the w.t. and bERKO mice was
quantified by measuring both the carotid medial area and the
VSMC proliferation 2 weeks after endothelial denudation (3, 4).
There were no differences observed in the medial areas of the
uninjured vessels of the w.t. and bERKO mice. In the w.t. mice,
injury induced an increase in medial area from 16.1 6 0.6 3 1023
mm2 in the w.t. uninjured to 20.0 6 0.9 3 1023 mm2 in the w.t.
injured 2E2; P , 0.05 (Fig. 3). E2 replacement inhibited the
increase in the medial area after injury in the w.t. mice to a value
indistinguishable from that of the uninjured vessels (17.8 6 0.6 3
1023 mm2; P , 0.05 vs. w.t. injured 2E2). In the bERKO mice,
injury also caused a significant increase in carotid medial area (from
16.8 6 0.6 3 1023 mm2 in the bERKO uninjured to 19.8 6 0.6 3
1023 mm2 in bERKO injured 2E2; P , 0.05 for injured vs.
uninjured; see Fig. 3). Just as in the w.t. mice, E2 treatment
prevented the increase in medial area after injury in the bERKO
animals (16.8 6 0.6 3 1023 mm2 bERKO injured 1E2; P , 0.05
for injured 1E2 vs. injured 2E2; P is not significant for injured 1E2
vs. uninjured). There were no significant differences between the
w.t. and bERKO mice for either the increase in carotid medial area
after injury or for suppression of this response by E2 treatment.
The extent of vascular cell proliferation was assessed 14 days
after vascular injury. BrdU-labeled cells were rarely detected
in the uninjured arteries of the w.t. and the bERKO mice
(average of ,1 labeled cell per vessel for both w.t. and
bERKO). As shown in Fig. 4, carotid injury induced a marked
increase in BrdU-labeled VSMCs in w.t. animals (to 59 6 10
cells per section; P , 0.05 for injured, 2E2 vs. uninjured). This
increase in VSMC proliferation was attenuated by E2 treat-
ment (to 27 6 5 cells per section; P , 0.05 for injured 1E2 vs.
injured 2E2). In the bERKO mice, the same pattern was seen;
injury caused substantial VSMC proliferation in placebo-
treated mice (to 46 6 10 cells per section; P , 0.05 for bERKO
injured 2E2 vs. bERKO uninjured), and E2 again inhibited
the injury-induced proliferation of VSMC in the bERKO mice
(to 15 6 3 cells per section; P , 0.05 for bERKO injured, 1E2
vs. bERKO injured 2E2; see Fig. 4). There were no significant
differences in the amount of VSMC proliferation between the
w.t. and bERKO animals within each treatment group. Thus,
for this second independent measure of vascular injury re-
sponse, E2 proved equally protective in the w.t. and bERKO
mice. A similar increase in the extent of endothelial cell
proliferation 14 days after injury was seen in both the placebo-
treated w.t. group (38 6 3 cells per section; P , 0.05 for injured
vs. uninjured) and bERKO (34 6 3 cells per section; P , 0.05
for injured vs. uninjured) carotid arteries. The extent of
endothelial cell labeling was also similar for the w.t. and
bERKO mice treated with E2 (39 6 2 and 37 6 2 cells per
section, respectively). Thus, there were no differences in the
extent of endothelial cell proliferation at 14 days after injury
between any of the groups (P is not significant for all com-
parisons). As shown previously (3, 4), only a minority of vessels
developed a detectable neointimal response after injury (9 of






Fig. 4. Medial smooth muscle cell proliferation in uninjured and injured w.t. and bERKO
mouse carotid arteries treated with vehicle or E2. (A–F) Representative segments of BrdU-
stained carotid artery sections are shown (3400). The number of BrdU-positive smooth muscle
cells for each section is listed. All BrdU counts were made for complete sections. (A) Wild-type,
uninjured(Uninj;0cells). (B)Wild-type injured,vehicle-treated(Inj,2E2;58cells). (C)Wild-type,
injured, E2-treated (Inj, 1E2; 29 cells). (D) bERKO (Uninj; 0 cells). (E) bERKO (Inj, 2E2; 45 cells).
(F) bERKO (Inj, 1 E2; 17 cells). (G) Summary medial VSMC BrdU labeling data for all w.t. and
bERKOmice.ThenumberofBrdU-labeledcellsdidnotdifferbetweenthew.t.andbERKOmice
in the injured, vehicle-treated groups (59 6 10 cells per section vs. 46 6 10 cells per section,
respectively) or in the injured E2-treated groups (27 6 5 cells per section vs. 15 6 3 cells per
section, respectively). *, P , 0.05, compared with both uninjured, and injured, estrogen-
treated groups within the same genotype; **, P , 0.05, compared with uninjured within the
same genotype.












The effects of estrogen on the cardiovascular system are diverse;
they include indirect effects on systemic factors as well as direct
effects on the vasculature (for review, see refs. 2, 17, and 18). The
direct effects of E2 on the vasculature include rapid effects on
vasomotor tone (19–22), and longer-term effects on atheroscle-
rosis (3, 4, 17, 18, 23–26) and vascular cell proliferation and
migration (17, 18, 27–32). The longer-term effects of estrogens
result from alterations in gene expression, and are believed to be
mediated by estrogen receptors, which are ligand-activated
transcription factors (33, 34). The data presented here show that
E2 inhibits equally well the response to vascular injury in
ERb-deficient mice and their littermate w.t. controls. We have
previously shown that estrogen inhibits the response to carotid
artery injury in w.t. mice (3, 4) and in mice devoid of ERa (4),
demonstrating that this vasoprotective effect of estrogen also
does not require ERa. After the identification of ERb, studies
demonstrated that ERb is expressed in the heart (refs. 35, 36,
and unpublished observations) as well as in the vasculature (4,
11, 36), and that ERb, but not ERa, mRNA levels are markedly
increased in vascular endothelial cells and in VSMCs after
vascular injury in male rats (11, 12). These data suggested to
many researchers that ERb may mediate the vasoprotective
effects of E2 (10, 13, 14). Several other observations also support
different functional roles for ERb and ERa. Although ERb and
ERa are highly homologous in some domains (e.g., the DNA-
binding domains), other regions of the proteins (e.g., the N
terminus) share little or no homology (5). In addition, the two
receptors differ with respect to their patterns of cell-specific
tissue expression (35–38), ligand-binding affinities (35, 39), and
gene targets (refs. 40, 41, and unpublished observations), further
supporting a potential role in the cardiovascular system for ERb
that is distinct from that for ERa.
The data presented here demonstrate equivalent inhibition by
estrogen of the response to vascular injury in bERKO and w.t. mice,
and show that ERb is not required for estrogen-mediated vasopro-
tection in this model. One explanation for these findings is that ERa
and ERb play redundant roles in mediating vascular protection by
estrogen, such that the presence of either ERa or ERb is sufficient
to achieve vascular protection. Such functional redundancy be-
tween ERa and ERb might reflect the fundamental biological
importance of the vasoprotective effect of estrogen. An alternative
to this hypothesis is that another, still unidentified estrogen receptor
(i.e., ‘‘ERg’’) mediates the vasoprotective effects of estrogen.
Differentiation of these two hypotheses will be addressed directly by
studying the effects of estrogen on the response to injury in mice
lacking both known estrogen receptors, when they become avail-
able. In summary, the present study shows that arterial injury leads
to similar increases in carotid medial area and smooth muscle cell
proliferation in w.t. and bERKO mice, and that these measures of
vascular injury are inhibited significantly and to the same degree by
E2 in both ERb-deficient animals and their w.t. littermates. Our
results suggest that either of the two known estrogen receptors,
ERa or ERb, is sufficient to protect against vascular injury, or that
an unidentified receptor for estrogen exists that mediates the
vasoprotective effects of estrogen.
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